Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Boosten maakt lagere dosering olaparib mogelijk
apr 2024 | Borstkanker, Gynaecologische oncologie, Uro-oncologie